MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression [Thoracic Oncology]

Conclusion
MET exon 14 mutations represent a clinically unique molecular subtype of NSCLC. Prospective clinical trials with c-Met inhibitors will be necessary to validate MET exon 14 mutations as an important therapeutic target in NSCLC.

Source: Journal of Clinical Oncology - February 22, 2016 Category: Cancer & Oncology Authors: Awad, Oxnard, Jackman, Savukoski, Hall, Shivdasani, Heng, Dahlberg, Janne, Verma, Christensen, Hammerman, Sholl Tags: Translational Oncology, Cancer Biomarkers, Oncogenes Thoracic Oncology Source Type: research